source
- AstraZeneca's breast cancer pill camizestrant fails to improve progression-free survival in pivotal SERENA-4 trialAstraZeneca announced that its oral estrogen receptor degrader camizestrant, marketed as Etcamah, did not meet its primary endpoint in the phase III SERENA-4 trial. The study evaluated camizestran…
- FDA approves Isembyld, first therapy to target muscle loss in SMA patientsScholar Rock received FDA approval for Isembyld, the first drug designed to address muscle loss in spinal muscular atrophy (SMA). The approval covers adults and children aged two years and older w…